208046-23-5

Usage

Uses

Used in Pharmaceutical Industry:
Tert-butyl 4-hydroxy-2-methylpiperidine-1-carboxylate is used as a chemical intermediate for the synthesis of various drugs due to its structural properties and reactivity. Its presence in the molecular structure of certain medications allows for the development of drugs targeting a range of medical conditions, leveraging its potential pharmacological properties.
The specific applications and industries where tert-butyl 4-hydroxy-2-methylpiperidine-1-carboxylate is utilized are not detailed in the provided materials. However, given its role as a pharmaceutical intermediate, it can be inferred that tert-butyl 4-hydroxy-2-Methylpiperidine-1-carboxylate contributes to the creation of medications for diverse therapeutic areas, including but not limited to cardiovascular, neurological, and anti-infective treatments. Its use would be integral in the development process, from the design of new drug candidates to their eventual production and distribution for medical use.

Upstream product

• 190906-92-4 tert-butyl 2-methyl-4-oxopiperidine-1-carboxylate 

Downstream Products

• 470477-66-8 4-(1-t-butoxycarbonyl-2-methylpiperidin-4-yloxy)-3-chloronitrobenzene 

Relevant academic research and scientific papers

THERAPEUTIC COMPOUNDS

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof in which m, n, W, X, Y, Z, R, R1, R2, R3 and R4 are as defined in the specification, for use in therapy.

SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof : (I) in which m, n, W, X, Y, Z, R1, R2, R3 and R4 are as defined in the specification, for use in the treatm

PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS

Novel compounds of structure Formula (I) or an enantiomer, a diastereomer, or a pharmaceutically acceptable salt thereof, wherein Z, R1, R2, R21, T1, T2, T3 and T4 are defined herein, are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR119 G protein-coupled receptor modulator therapy. Thus, the disclosure also concerns compositions comprising these novel compounds and methods of treating diseases or conditions related to the activity of the GPR119 G protein-coupled receptor by using any of these novel compounds or a composition comprising any of such novel compounds.

BENZAMIDINE DERIVATIVE

Compounds of general formula (1) and pharmacologically acceptable salts thereof: ???[wherein ??????R1 represents a hydrogen atom, a halogen atom, an alkyl group or a hydroxyl group; ??????R2 represents a hydrogen atom or a halogen atom; ??????R3 represents a hydrogen atom, an alkyl group which may be substituted, an aralkyl group, an alkylcarbonyl group which may be substituted, an alkylsulfonyl group which may be substituted or the like; ??????each of R4 and R5 represents a hydrogen atom, a halogen atom, an alkyl group which may be substituted, a carbamoyl group or the like; ??????R6 represents a heterocycle or the like; ??????each of R7 and R8 represents a hydrogen atom, an alkyl group or the like; ??????n represents 0, 1 or 2] ???exhibit excellent activated blood coagulation factor X inhibitory activity and are useful for the prevention or treatment of blood coagulation-related diseases.

Aminooxy piperidines as ornithine decarboxylase inhibitors

The invention relates to compounds of formula I STR1 wherein either R1 is a radical of formula Ia, in which n is 0 or 1, is hydrogen and R2 is a radical of formula Ib, in which p is 1 or 2, and wherein R is C1 -C2/su